# The two companies have been in discussions about a potential deal that could be weeks away, the report said.

*business · news · 2026-05-22 · Reuters*

## Key points

- Lantheus and Curium are in advanced deal discussions that could conclude within weeks.
- Curium was valued at about $7 billion in 2023 during a CapVest Partners fundraising round.
- The FDA extended review of Lantheus' LNTH-2501 imaging kit to June 29 for manufacturing concerns.
- The FDA approved a new Pylarify formulation in March to increase prostate cancer scan production.

The two companies have been in discussions about a potential deal that could be weeks away, the report said, citing people familiar with the ​matter. No final decision has been made and there is no ​guarantee the talks will result in a transaction, the report ⁠said. Sign up here. Lantheus declined to comment. Shares of the company, which has a market ​capitalization of about $6.15 billion, were trading nearly 2% down in extended trading. Curium was ​valued at about $7 billion last year when its owner, CapVest Partners, raised funds for a continuation vehicle for the nuclear medicine company, the report said. Curium did not respond ​to a Reuters request for comment. Lantheus beat analysts' expectations for first-quarter adjusted ​profit earlier this month, helped by demand for its cancer imaging agent. "2026 is a ‌year of ⁠commercial execution and regulatory milestones," said interim CEO Mary Heino on the earnings call. "We're making deliberate choices about where we focus our commercial efforts and deploying capital, so we're positioned to deliver solid results in 2026 and ​accelerate growth in ​2027." Lantheus, however, reiterated ⁠its annual earnings forecast, while the company acknowledged, according to a William Blair analyst, that an upward revision is ​overdue but will not occur until a permanent CEO is ​appointed. In ⁠March, the U.S. FDA extended its review of Lantheus' diagnostic imaging kit, LNTH-2501, by three months to allow more time to assess manufacturing-related information. The decision is ⁠now expected ​by June 29. Separately in March, the regulator approved ​a new formulation of the company's prostate cancer imaging agent, Pylarify, aimed at expanding scanning access ​through increased production capacity. Reporting by Siddhi Mahatole in Bengaluru; Editing by Shilpi Majumdar

**Companies:** Lantheus, Curium
**Countries:** United States

[Read the full story on Reuters](https://www.reuters.com/legal/transactional/lantheus-weighs-potential-7-billion-sale-bloomberg-news-reports-2026-05-22/)

---

Canonical: https://newsio.io/n/3c96c42a-b0cd-4a40-8424-0e36872b35a9/the-two-companies-have-been-in-discussions-about-a-potential-deal-that-could-be
Summarized by Newsio from Reuters. https://newsio.io/how-it-works